Levosimendan Amdipharm

Levosimendan, the active ingredient in Levosimendan Amdipharm, is a calcium sensitizer (inodilator) presented as an intravenous solution for intravenous administration. It is used to improve cardiac contractility in patients with acute decompensated heart failure or cardiogenic shock, particularly when conventional therapies are insufficient.

GNH USA supplies Levosimendan Amdipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring quality and regulatory compliance across global markets.

Levosimendan acts on the cardiovascular system to enhance cardiac output in severe heart failure states.

Acute decompensated heart failure: improves contractility and reduces symptoms. Cardiogenic shock: provides inotropic support and vasodilation to stabilize hemodynamics. Low cardiac output syndrome: enhances myocardial performance without raising intracellular calcium levels.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Hypotension: drop in blood pressure, especially after infusion start. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Arrhythmia: non‑life‑threatening rhythm changes. - Flushing: transient skin redness.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Pulmonary edema: worsening respiratory status. - Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan requires careful monitoring in several clinical situations.

Monitor blood pressure: watch for significant hypotension. Assess cardiac rhythm: risk of arrhythmias during infusion. Evaluate renal function: dosage may need adjustment in impairment. Avoid in severe hypotension: contraindicated when systolic pressure is very low. Use cautiously in hepatic impairment: limited safety data. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents.

Major Interactions (Avoid): - Concomitant potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Combination with other inotropes (e.g., dobutamine): increased risk of arrhythmia. - CYP450 inhibitors (e.g., ketoconazole): may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt therapeutic effect. - Diuretics: can exacerbate electrolyte disturbances. - Anticoagulants: may increase bleeding tendency due to vasodilation.